Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcasertib in advanced GIST
NCT02232620Phase 2Terminated
- Sponsor
- Sumitomo Pharma America
- Start
- Mar 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amcasertib in gastrointestinal stromal tumor (GIST), sponsored by Sumitomo Pharma America. Started Mar 2017; status: terminated.
02
Drugs
amcasertib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02232620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232620.